Table 2.

Clinical manifestations in patients with isolated IgA positivity^*

Clinical manifestations†	LUMINA n = 23	Hopkins n = 17	APLS n = 17
All thrombosis (arterial and/or venous)	6 (26.1)	12 (70.6)	6 (35.3)
Pregnancy loss/ complications	3 (13.0)	9 (52.9)	1 (5.8)
Stroke	1 (4.3)	4 (23.5)	2 (11.7)
Seizure	1 (4.3)	6 (35.3)	0 (0)
Myocardial infarction	2 (8.7)	4 (23.5)	0 (0)
Valvular heart disease	1 (4.3)	1 (5.8)	0 (0)
Pulmonary Arterial hypertension	0 (0)	5 (29.4)	0 (0)
Skin ulcers	1 (4.3)	0 (0)	0 (0)
Livedo reticularis	N/A	3 (17.6)	0 (0)
Thrombocytopenia	5 (21.7)	7 (41.2)	2 (11.7)
ESRD	0 (0)	3 (17.6)	1 (5.8)
SLAM-R (mean±SD)	7.30 ± 5.49	N/A	N/A
SELENA-SLEDAI (mean±SD)	N/A	4.04 ± 3.53	N/A

^*Except where indicated otherwise, values are the number (%) of patients.

LUMINA = Lupus in Minorities, Nature versus nurture; APLS = Antiphospholipid Standardization Laboratory; NA = not available; ESRD: end-stage renal disease; SLAM-R: Systemic Lupus Activity Measure, Revised; SELENA-SLEDAI: Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index.

^†Includes traditional and non-traditional antiphospholipid syndrome-associated manifestations